AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00779818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Treatment by laser
Study NCT03864627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
Study NCT03864627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
Study NCT03452995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHYSIOTHERAPY
Description: Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
Study NCT03452995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHYSIOTHERAPY
Description: Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
Study NCT02106845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
Study NCT02106845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
Study NCT02106845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Once daily orally 160 mg (4 tablets 40 mg)
Study NCT03821350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information leaflet
Description: The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
Study NCT01199198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Starting dose 15 mg by mouth once a day for 14 days.
Study NCT01199198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth once a day for 14 days.
Study NCT02766049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC
Description: Autologous dendritic cells (3x10e7)
Study NCT02179268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50mg, 50-150mg/d,qd for one year
Study NCT02179268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20mg, 20-40mg/d,qd,for one year
Study NCT02766049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC10e6+HIV-AT2
Description: Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
Study NCT02766049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC10e7+HIV-AT2
Description: Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
Study NCT02468687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-methyl-pyrrolidone
Description: NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
Study NCT04170491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous EEG
Description: Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
Study NCT00865995 — intervention group
Intervention type: PROCEDURE
Intervention: Tracheal Lavage
Description: Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
Study NCT02179268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: venlafaxine,25mg, 75-100mg/d, bid, for one year
Study NCT02179268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reboxetine
Description: reboxetine,4mg, 4-8mg/d,qd for one year
Study NCT02179268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 50min, every week for three months, every month, for nine months
Study NCT02089035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA-rich dairy products (UHT milk, cheese and butter)
Study NCT04210037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
Study NCT04210037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m˄2 on days 1 and 8 of a 21-day cycle
Study NCT02210442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educaguia intervention
Description: Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
Study NCT02210442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
Study NCT02587169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib-adriamycin
Description: The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
Study NCT02089035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional dairy products (UHT milk, cheese, butter)
Study NCT02940132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC10914
Description: SC10914 will be administered orally.
Study NCT03040700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myocardial Perfusion Scan
Description: Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
Study NCT03040700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Description: Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
Study NCT02145052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suture
Description: A continuous suture is considered standard of care.
Study NCT02145052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture
Description: Interrupted sutures are considered standard of care.
Study NCT01963182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01884324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Delivery
Description: This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion.
Study NCT02456207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT400
Study NCT00506792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAU145
Study NCT00506792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01504958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS.
Study NCT02456207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02520869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: swim-up technique
Description: swim-up technique used
Study NCT02520869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zeta test technique
Description: zeta test technique used
Study NCT00428571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic gastric bypass surgery
Description: Laparoscopic Gastric Bypass Surgery
Study NCT00428571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic adjustable gastric banding
Description: laparoscopic adjustable gastric banding
Study NCT00428571 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intensive Medical Management
Description: lifestyle, diet, medication optimization
Study NCT02217423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy chest wall expansion
Description: chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
Study NCT02217423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy airway clearance modality
Description: The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
Study NCT04791215 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
Study NCT01504958 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS.
Study NCT01504958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NICE Cognitive Training
Description: 12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group.
Study NCT01504958 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: NICE Cognitive Training
Description: 12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group.
Study NCT00804128 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI
Study NCT00804128 — intervention group
Intervention type: DRUG
Intervention: Gadavist
Description: Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging
Study NCT03463109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrocutaneous stimulation
Description: Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
Study NCT03463109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment + Electrocutaneous stimulation
Description: Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
Study NCT01337791 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Telbivudine treatment
Description: Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
Study NCT02039089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 2.5 mg
Study NCT02831855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
Study NCT02831855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
Study NCT02831855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
Study NCT02253433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Clinic Care
Description: The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
Study NCT02253433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Clinic Care + Home Intervention
Description: The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
Study NCT04191304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
Study NCT04191304 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
Study NCT03920579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326, D337 and D013
Description: A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
Study NCT02039089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 10 mg
Study NCT02039089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 25 mg
Study NCT02039089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04257006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris membrane
Description: Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
Study NCT00748449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: 1 Colonoscopy
Study NCT00748449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-colonography
Description: 1 CT-colonography; Procedure/Surgery/Radiation
Study NCT01089751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trospium chloride
Description: Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
Study NCT01089751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo once daily on an empty stomach for 14 weeks.
Study NCT01131130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational contact lens
Description: After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
Study NCT01131130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Contact Lens
Description: After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
Study NCT01131130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
Study NCT02825238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Study NCT05554744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle injection
Description: Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
Study NCT03380169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic advance wound dressing
Description: A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
Study NCT03380169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic conventional wound dressing
Description: Conventional gauze dressing
Study NCT01960556 — intervention group
Intervention type: OTHER
Intervention: Simulation Training
Description: Simulation training provided to one group
Study NCT01510561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4
Description: 90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
Study NCT01510561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4
Study NCT01510561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4 + gemcitabine
Study NCT01188902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: walnut
Description: walnut consumption 48 g/d
Study NCT02363972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellipsys Vascular Access Catheter
Description: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.